News | Press releases & other news

Press releases

• Apr 21, 2026

  Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026Read more...

• Apr 20, 2026

  Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced MelanomaRead more...

• Apr 16, 2026

  Lytix Biopharma ASA - Conversion to public limited liability company and name change registeredRead more...

• Apr 14, 2026

  Lytix Biopharma AS: Minutes from Annual General MeetingRead more...

• Apr 9, 2026

  Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONSRead more...

• Apr 7, 2026

  Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of GrowthRead more...

• Mar 25, 2026

  Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026Read more...

• Mar 23, 2026

  Lytix Biopharma AS: Annual Report for 2025Read more...

• Mar 17, 2026

  Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026Read more...

• Feb 24, 2026

  Lytix Biopharma AS - New share capital registeredRead more...

• Feb 16, 2026

  Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)Read more...

• Feb 11, 2026

  Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim ReportRead more...

• Feb 10, 2026

  Lytix Biopharma AS - Final result of Subsequent Offering and allocation of Offer SharesRead more...

• Feb 9, 2026

  Lytix Biopharma AS - Last day of the Subscription Period in the Subsequent OfferingRead more...

• Feb 5, 2026

  Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 ReportRead more...

• Jan 27, 2026

  Lytix Biopharma AS - Publication of Prospectus regarding Subsequent Offering and commencement of Subscription PeriodRead more...

• Jan 26, 2026

  Lytix Biopharma AS - EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization ApprovedRead more...

• Jan 14, 2026

  Lytix Biopharma AS - New share capital registeredRead more...

• Jan 12, 2026

  Lytix Biopharma AS - Notice of extraordinary general meeting 26 January 2026Read more...

• Jan 7, 2026

  Finansiell kalenderRead more...